Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation and cardiovascular risk in obese adults with metabolic syndrome: A randomized clinical trial (PROSIR)

Jiménez, Carmen Tenorio; Martínez-Ramírez, M.J.; Tercero-Lozano, Mercedes; Arraiza-Irigoyen, Carmen; Castillo-Codes, Isabel Del; Olza, J.; Plaza‐Díaz, Julio; Olivares, Manuel; Gil, Andrea Paola Rojas; Gómez-Llorente, Carolina

doi:10.1016/j.clnu.2018.06.1118

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Probiotics have displayed promising potential in mitigating cardiovascular disease risks, including improving blood pressure, glycemic and lipid profiles. Recent studies have provided support for these findings, with improved glycemic control seen in both obese and T2DM patients who were on probiotic supplementation, compared to diet-alone measures 28 , 29 . Another recent meta-analysis also demonstrated a significant decrease in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels among hypercholesterolemic adults who consumed probiotics 30 .…”

Section: Probiotics and Their Potential Effects On Cardiovascular Dis...mentioning

confidence: 89%

Unlocking the gut-heart axis: exploring the role of gut microbiota in cardiovascular health and disease

Shariff,

Kwan Su Huey,

Parag Soni

et al. 2024

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Introduction: Gut microbiota has emerged as a pivotal player in cardiovascular health and disease, extending its influence beyond the gut through intricate metabolic processes and interactions with the immune system. Accumulating evidence supports a significant association between gut microbiota and cardiovascular diseases such as atherosclerosis, hypertension, and heart failure. Dietary patterns have been identified as key factors shaping the composition of the gut microbiota and exerting notable impacts on cardiovascular health. Probiotics and prebiotics have shown promise in mitigating the risks of cardiovascular disease by modulating key cardiovascular parameters. Fecal microbiota transplantation (FMT) has recently emerged as a novel and intriguing therapeutic strategy. Aim: This review paper aims to explore and elucidate the multifaceted role of gut microbiota in cardiovascular health. It will also address the prevailing challenges and limitations in gut microbiota studies, emphasizing the importance of future research in overcoming these obstacles to expand our understanding of the gut-heart axis. Materials and methods: A comprehensive literature search was conducted using various databases including ClinicalTrials, Google Scholar, PubMed, ScienceDirect, MEDLINE, and Ovid Resources. The search strategy included utilizing keywords such as “Gut microbiota,” “Randomized controlled trials (RCTs),” “Gut-heart axis,” “Dysbiosis,” “Diet,” “Probiotics,” “Prebiotics,” “Fecal Microbiota transplantation,” “cardiovascular disease,” “Meta-analyses,” and other compatible terms thereof. Only articles written in English were considered, and selection criteria included relevance to the research objectives, reasonable sample sizes, and robust methodology. In addition to the identified articles, meta-analyses, animal models and studies, and references from the selected articles were also examined to ensure a comprehensive review of the literature. Results: Dietary patterns exert a significant influence on the composition of the gut microbiota, and certain diets, such as the Mediterranean diet, have been associated with a favorable gut microbiota profile and a reduced risk of cardiovascular disease (CVD). Probiotics and prebiotics have emerged as potential interventions to mitigate CVD risks by modulating blood pressure, glycemic control, lipid profiles, and gut dysbiosis. Another innovative therapeutic approach is fecal microbiota transplantation (FMT), which involves transferring fecal material from a healthy donor to restore a balanced gut microbiota. FMT holds promise for improving cardiometabolic parameters in individuals with CVD, although further research is needed to elucidate its precise mechanisms and assess its effectiveness. Conclusion: The gut microbiota is emerging as a potential therapeutic target for CVD prevention and management. However, current research has limitations, including the need for larger and more diverse studies, the challenges of establishing causality, and concerns regarding the long-term consequences and safety of gut microbiota modulation. Despite these limitations, understanding the gut-heart axis holds promise for the development of personalized therapies and interventions for cardiovascular health. Further research is needed to expand our knowledge and address the ethical and safety issues associated with gut microbiota modification.

show abstract

Section: Probiotics and Their Potential Effects On Cardiovascular Dis...mentioning

confidence: 89%

Unlocking the gut-heart axis: exploring the role of gut microbiota in cardiovascular health and disease

Shariff,

Kwan Su Huey,

Parag Soni

et al. 2024

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

“…Tenorio-Jimenez et al [ 12 ] report that the 12-week administration of a daily dose of 5 × 10 9 cfu L. reuteri V3401 in capsules was associated with lower levels of inflammation biomarkers, such as TNF-, IL-6, IL-8, and soluble intercellular adhesion molecule-1 (sICAM-1), and a reduced risk of CVD in obese adults aged 18 to 65 years with metabolic syndrome. Szulinska et al [ 13 ] also discovered that treatment with the multispecies probiotic Ecologic ® Barrier modified both the functional and biochemical markers of vascular dysfunction in 81 obese postmenopausal Caucasian women.…”

Section: Reduction In the Risk Factors Of Cvdsmentioning

confidence: 99%

Clinical Evidence on the Potential Beneficial Effects of Probiotics and Prebiotics in Cardiovascular Disease

Pavlidou

Fasoulas

Mantzorou

et al. 2022

IJMS

View full text Add to dashboard Cite

The ‘gut microbiome’—the hundreds of trillions of bacteria in the human gastrointestinal tract—serves several functions. The gut microbiome includes all the microorganisms, bacteria, viruses, protozoa, and fungi in the gastrointestinal tract and their genetic material. It helps digest indigestible foods and produces nutrients. Through the metabolism of sugars and proteins, it helps the intestinal barrier, the immune system, and metabolism. Some bacteria, such as those in the gut microbiome, cause disease, but others are essential to our health. These “good” microbes protect us from pathogens. Numerous studies have linked an unhealthy gut microbiome to obesity, insulin resistance, depression, and cardiometabolic risk factors. To maximize probiotic benefits in each case, knowledge of probiotic bacterial strains and how to consume them should be increased. This study aims to examine the benefits of probiotic and prebiotic organisms on cardiovascular health, specifically on heart disease, coronary heart disease, stroke, and hypertension. To complete the research, a literature review was conducted by gathering clinical studies and data. The clinical evidence demonstrates the beneficial effect of probiotics and prebiotic microorganisms on the gut microbiome, which has multiple benefits for overall health and especially for cardiovascular diseases.

show abstract

Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation and cardiovascular risk in obese adults with metabolic syndrome: A randomized clinical trial (PROSIR)

Cited by 2 publications

References 0 publications

Unlocking the gut-heart axis: exploring the role of gut microbiota in cardiovascular health and disease

Unlocking the gut-heart axis: exploring the role of gut microbiota in cardiovascular health and disease

Clinical Evidence on the Potential Beneficial Effects of Probiotics and Prebiotics in Cardiovascular Disease

Contact Info

Product

Resources

About